Non-transmissible MV Vector with Segmented RNA Genome Establishes Different Types of iPSCs from Hematopoietic Cells.


Journal

Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581

Informations de publication

Date de publication:
08 01 2020
Historique:
received: 24 06 2018
revised: 30 08 2019
accepted: 06 09 2019
pubmed: 5 11 2019
medline: 22 12 2020
entrez: 4 11 2019
Statut: ppublish

Résumé

Recent advances in gene therapy technologies have enabled the treatment of congenital disorders and cancers and facilitated the development of innovative methods, including induced pluripotent stem cell (iPSC) production and genome editing. We recently developed a novel non-transmissible and non-integrating measles virus (MV) vector capable of transferring multiple genes simultaneously into a wide range of cells through the CD46 and CD150 receptors. The MV vector expresses four genes for iPSC generation and the GFP gene for a period of time sufficient to establish iPSCs from human fibroblasts as well as peripheral blood T cells. The transgenes were expressed differentially depending on their gene order in the vector. Human hematopoietic stem/progenitor cells were directly and efficiently reprogrammed to naive-like cells that could proliferate and differentiate into primed iPSCs by the same method used to establish primed iPSCs from other cell types. The novel MV vector has several advantages for establishing iPSCs and potential future applications in gene therapy.

Identifiants

pubmed: 31677955
pii: S1525-0016(19)30410-1
doi: 10.1016/j.ymthe.2019.09.007
pmc: PMC6952176
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

129-141

Informations de copyright

Copyright © 2019 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Références

Cell Stem Cell. 2009 Jan 9;4(1):16-9
pubmed: 19097958
Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4484-9
pubmed: 24623855
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Cell Stem Cell. 2009 Oct 2;5(4):353-7
pubmed: 19796614
Expert Opin Biol Ther. 2013 Apr;13(4):483-502
pubmed: 23289598
Curr Gene Ther. 2012 Oct;12(5):410-6
pubmed: 22920683
Cell Stem Cell. 2010 Nov 5;7(5):618-30
pubmed: 20888316
Mol Ther. 2008 Aug;16(8):1427-36
pubmed: 18578012
Science. 1982 Mar 26;215(4540):1577-85
pubmed: 7041255
Cell Stem Cell. 2010 Jul 2;7(1):15-9
pubmed: 20621044
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18283-8
pubmed: 21990348
Nat Struct Mol Biol. 2013 Sep;20(9):1131-9
pubmed: 23934149
Nat Methods. 2017 Nov;14(11):1055-1062
pubmed: 28945704
Nature. 2013 Dec 12;504(7479):282-6
pubmed: 24172903
Cell Stem Cell. 2010 Jul 2;7(1):20-4
pubmed: 20621045
Nature. 2000 Aug 24;406(6798):893-7
pubmed: 10972291
Hum Vaccin Immunother. 2016 May 3;12(5):1102-16
pubmed: 26631840
J Virol. 2007 Jul;81(13):6827-36
pubmed: 17442724
J Virol. 2007 Mar;81(6):2564-72
pubmed: 17182683
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Science. 2009 May 8;324(5928):797-801
pubmed: 19325077
Nature. 1999 Oct 14;401(6754):708-12
pubmed: 10537110
Blood. 2009 May 28;113(22):5476-9
pubmed: 19299331
Cell Stem Cell. 2013 Jan 3;12(1):114-26
pubmed: 23290140
Cell. 2015 Jul 16;162(2):452-453
pubmed: 28843285
Blood. 2011 Jan 20;117(3):808-14
pubmed: 20971955
J Gen Virol. 2003 Oct;84(Pt 10):2691-703
pubmed: 13679603
Nat Protoc. 2012 Mar 15;7(4):718-28
pubmed: 22422317
Cell. 2013 Apr 11;153(2):335-47
pubmed: 23582324
Nat Rev Mol Cell Biol. 2016 Mar;17(3):170-82
pubmed: 26818440
Nat Rev Dis Primers. 2016 Jul 14;2:16049
pubmed: 27411684
J Virol. 2000 Jul;74(14):6643-7
pubmed: 10864679
Microbiol Immunol. 2003;47(8):613-7
pubmed: 14524622
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Genome Biol. 2004;5(10):R80
pubmed: 15461798
PLoS Pathog. 2011 Aug;7(8):e1002240
pubmed: 21901103
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Cell Stem Cell. 2009 May 8;4(5):381-4
pubmed: 19398399
Cell Stem Cell. 2008 Feb 7;2(2):151-9
pubmed: 18371436
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Sci Rep. 2016 Nov 24;6:37163
pubmed: 27883010
Blood. 2014 Jun 12;123(24):3750-9
pubmed: 24782509
Science. 2008 Nov 7;322(5903):949-53
pubmed: 18845712
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
Nat Biotechnol. 2007 Jun;25(6):681-6
pubmed: 17529971
J Virol. 2006 May;80(9):4242-8
pubmed: 16611883
J Virol. 2011 Nov;85(22):11871-82
pubmed: 21917959
J Virol. 2011 Oct;85(19):10409-14
pubmed: 21775447
J Virol. 2002 Jul;76(13):6743-9
pubmed: 12050387
Bioinformatics. 2003 Jan 22;19(2):185-93
pubmed: 12538238
Nat Genet. 2002 Dec;32 Suppl:496-501
pubmed: 12454644
Science. 2003 Oct 17;302(5644):415-9
pubmed: 14564000
Proc Natl Acad Sci U S A. 2010 May 18;107(20):9222-7
pubmed: 20442331
Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):348-62
pubmed: 19838014
J Gen Virol. 1990 Dec;71 ( Pt 12):3071-4
pubmed: 1703217

Auteurs

Takafumi Hiramoto (T)

Department of Biochemistry, Jichi Medical University, Tochigi 329-0498, Japan.

Maino Tahara (M)

Department of Virology 3, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.

Jiyuan Liao (J)

Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.

Yasushi Soda (Y)

Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.

Yoshie Miura (Y)

Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.

Ryo Kurita (R)

Central Blood Institute (Blood Service Headquarters), Japanese Red Cross Society, Tokyo 135-8521, Japan.

Hiroshi Hamana (H)

Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.

Kota Inoue (K)

Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

Hiroshi Kohara (H)

Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.

Shohei Miyamoto (S)

Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.

Yasuki Hijikata (Y)

Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.

Shinji Okano (S)

Section of Pathology, Department of Morphological Biology, Fukuoka Dental College, Fukuoka 814-0193, Japan.

Yoshiyuki Yamaguchi (Y)

Angel Hospital, Fukuoka 812-8582, Japan.

Yoshinao Oda (Y)

Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

Kenji Ichiyanagi (K)

Laboratory of Genome and Epigenome Dynamics, Department of Applied Molecular Biosciences, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Japan.

Hidehiro Toh (H)

Division of Epigenetics and Development, Medical Institute of Bioregulation, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

Hiroyuki Sasaki (H)

Division of Epigenetics and Development, Medical Institute of Bioregulation, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

Hiroyuki Kishi (H)

Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.

Akihide Ryo (A)

Department of Microbiology, Yokohama City University, Kanagawa 236-0004, Japan.

Atsushi Muraguchi (A)

Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.

Makoto Takeda (M)

Department of Virology 3, National Institute of Infectious Diseases, Tokyo 208-0011, Japan. Electronic address: mtakeda@nih.go.jp.

Kenzaburo Tani (K)

Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan. Electronic address: k-tani@ims.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH